Business Context and Reporting Period
This Form 8-K Current Report from KALA BIO, Inc. (KALA) covers the event date of August 27, 2026. The Company is a Delaware corporation with its principal executive offices in Arlington, MA, and its common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material event is the Company's failure to meet the Nasdaq Minimum Bid Price Requirement (Rule 5550(a)(2)). The closing bid price of the Common Stock remained below $1.00 per share for 30 consecutive business days from July 16, 2026, through August 26, 2026. Consequently, the Nasdaq Staff determined the Company is not eligible for the standard 180-day compliance period because the Company executed a 1-for-50 reverse stock split on May 11, 2026, within the prior one-year period.
Outlook, Risks, and Management Commentary
Management intends to timely request a hearing before the Nasdaq Hearings Panel to appeal the Staff's determination. A timely request will stay any suspension or delisting action pending the Panel's decision. The Company explicitly states there can be no assurance that the request for continued listing will be granted or that it will regain compliance with the Minimum Bid Price Requirement. Forward-looking statements regarding the outcome of the hearing are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the status of the appeal hearing request with the Nasdaq Hearings Panel.
- Monitor the daily closing bid price of KALA stock to assess the likelihood of regaining compliance.
- Review the Company's recent 10-K and 10-Q filings for underlying financial performance issues contributing to the low stock price.
- Confirm whether the Company has disclosed any additional capital raising plans or strategic alternatives to address the listing deficiency.